Article

Gilbert’s Syndrome Leads to Elevated Bilirubin after Initiation of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis

2023-06-27

Abstract excerpt

Nine people with cystic fibrosis (pwCF) were found to have isolated elevations in serum total bilirubin after starting elexacaftor/tezacaftor/ivacaftor (ETI) that were associated with Gilbert’s Syndrome. In longitudinal examination, total bilirubin levels increased substantially after initiation of ETI without elevations in liver transaminases in those with this syndrome. Because elevated bilirubin levels in Gilbe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c222e562-db9a-5574-8715-17ffdedfe242
DOI: 10.22541/au.168787808.82841587/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Gilbert’s Syndrome Leads to Elevated Bilirubin after Initiation of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic FibrosisDOI 10.22541/au.168787808.82841587/v1Read

Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.Semantic proximity Read

Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert’s syndromeSemantic proximity Read

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis.Semantic proximity Read

Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM.Semantic proximity Read

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.Semantic proximity Read

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre.Semantic proximity Read

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.Semantic proximity Read

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.Semantic proximity Read

Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.Semantic proximity Read

Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis.Semantic proximity Read

Clinical and biochemical response to elexacaftor/tezacaftor/ivacaftor in a patient with the rare L927P/N1303K CFTR genotype.Semantic proximity Read

Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read